Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Oligodendroglioma

Academic Article
Publication Date:
2008
Short description:
Oligodendroglioma / Van den Bent, M.j., Reni, M., Gatta, G., Vecht, C.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 66:3(2008), pp. 262-272. [10.1016/j.critrevonc.2007.11.007]
abstract:
Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
Iris type:
1.1 Articolo in rivista
List of contributors:
Van den Bent, Mj; Reni, M; Gatta, G; Vecht, C
Authors of the University:
RENI MICHELE
Handle:
https://iris.unisr.it/handle/20.500.11768/124068
Published in:
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.7.0.0